LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) issued a statement on the jury
verdict in the Valadez case in Illinois state court finding in GSK's favour. The
Illinois state court found GSK not liable for plaintiff's colorectal cancer. The
court rejected the Plaintiff's ability to request punitive damages. GSK said the
outcome from the trial is consistent with the scientific consensus that there is
no consistent or reliable evidence that ranitidine increases the risk of any
cancer.

Separately, GSK plc welcomed the recent court ruling dismissing the next Zantac
trial that was due to start on 23 May 2024. In the Williams case, the Illinois
state court dismissed the case before trial on the basis that GSK was not the
brand manufacturer of over-the-counter Zantac at the time the Plaintiff
allegedly used it.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX